We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    APACaP
Previous Study | Return to List | Next Study

Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02184663
Recruitment Status : Recruiting
First Posted : July 9, 2014
Last Update Posted : February 2, 2018
Information provided by (Responsible Party):
GERCOR - Multidisciplinary Oncology Cooperative Group

Brief Summary:

Adapted Physical Activity (APA) program may provide an opportunity to improve symptoms for patients with unresectable pancreatic cancer.

Thereby, it is proposed to conduct an open trial to assess effects of the APA program in such population

Condition or disease Intervention/treatment
Unresectable Locally Advanced Cancer Metastatic Pancreatic Cancer Other: without APA program Other: APA program

Detailed Description:

The benefit of Adapted Physical Activity (APA) has been demonstrated after cancer diagnosis in term of symptomatic improvement: reducing fatigue, pain and improving the quality of life, psychological and emotional state, and adherence to treatment.

The aim of the study is to assess the effects of an APA program in pancreatic cancer population treated by usual chemotherapy.

200 randomized patients are required.

The program is organized in 16 weeks. During the trial, assessments include: aerobic exercises, muscular strength, six-minute walk test, body composition (bioimpedance, L3 CT-scan), level of physical activity - International Physical Activity Questionnaire - (IPAQ questionnaire), fatigue - Multidimensional Fatigue Inventory - (MFI-20 questionnaire), quality of life - EORTC Quality of Life questionnaire C-30 - (EORTC QLQ-30 questionnaire), depression symptom - Hospital Anxiety and depression scale - (HADS questionnaire), pain (Brief Pain Inventory Short form), and nutritional evaluation (BMI, ingests EVA).

Furthermore, relationships between insulin resistance, insulin secretion, Insulin like Growth Factor 1 (IGF-1) and pancreatic carcinogenesis exist. APA may improve the quality of life in decreasing insulin-resistance, insulin secretion and IGF-1.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Study Start Date : September 2014
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Standard care without APA program Other: without APA program
Control Arm : chemotherapy alone
Experimental: standard care with APA program Other: APA program
Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)

Primary Outcome Measures :
  1. Multidimensional Fatigue Inventory - (MFI-20 questionnaire) [ Time Frame: At 16 weeks ]
  2. Quality of life - EORTC Quality of Life Questionnaire C-30 - (EORTC QLQ-30 questionnaire) [ Time Frame: At 16 weeks ]

Secondary Outcome Measures :
  1. Time To deterioration (TTD) [ Time Frame: Up to 24 months ]
  2. Brief Pain Inventory Short form questionnaire [ Time Frame: Up to 24 months ]
  3. Patient depression scale - HADS questionnaire [ Time Frame: Up to 24 months ]
  4. Nutritional status evaluation [ Time Frame: up to 24 months ]
    Nutritional Status will be measured by weigth, Body Mass Index, body composition, EVA ingests, caloric intake and protidic, albumin/prealbumin, inflammation markers (PNN and CRP)

  5. Physical Activity evaluation - IPAQ questionnaire [ Time Frame: up to 24 months ]
    Six minutes walk test, dyspnea scale, Borg scale, muscular pain, strength test with bands and compliance program

  6. Number of Adverse events (AE) grade 3 -4 [ Time Frame: up to 24 months ]
  7. Progression free survival (PFS) [ Time Frame: 2 years ]
  8. Overall Survival (OS) [ Time Frame: 2 years ]
  9. Accompanying partner depression scale (HADS questionnaire) [ Time Frame: up to 24 months ]
  10. General state - Performance status OMS [ Time Frame: up to 24 months ]
  11. Fatigue scale (EVA fatigue) [ Time Frame: up to 24 months ]
  12. MFI-20 and EORTC QLQ C-30 evaluation [ Time Frame: at 6, 12 et 24 months ]
  13. medico-economic evaluation [ Time Frame: up to 24 months ]
  14. visual analog scale for pain [ Time Frame: up to 24 months ]
  15. analgesic consumption [ Time Frame: up to 24 months ]
  16. anxiolytic / antidepressant consumption [ Time Frame: up to 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven non resectable pancreatic adenocarcinoma
  • Indication of palliative chemotherapy
  • Life expectancy ≥ 3 months
  • Eastern Cooperative oncology group (ECOG) - Performance status ≤2
  • Age ≥18 years old
  • At least one measurable lesion as assessed by CT-scan or MRI (Magnetic resonance Imaging)
  • Identified Accompanying partner Adapted Physical Activity (AAPA)
  • Signed and dated informed consent
  • Registration in a National Health Care System (CMU included for France)

Exclusion Criteria:

  • Previous Cerebrovascular accident or myocardial infarction <6months
  • Uncontrolled hypertension.
  • Severe cardiovascular or respiratory disease
  • Severe cognitive or psychiatric disorder
  • Severe motor and/or sensory neuropathy
  • Rheumatologic or orthopedic problem or bone lesions with a fracture risk
  • Others comorbidities contra-indicated physical exercises
  • Patient protected by the law - Guardianship and trusteeship

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02184663

Contact: Pascal HAMMEL, PhD +33140875651 pascal.hammel@bjn.aphp.fr

Polyclinique Bordeaux Nord Aquitaine Recruiting
Bordeaux, France
Contact: Cédric LECAILLE, MD         
Principal Investigator: Cédric LECAILLE, MD         
CHU Morvan Recruiting
Brest, France
Contact: Jean Philippe METGES, MD         
Principal Investigator: Jean Philippe METGES, MD         
Hôpital Beaujon Recruiting
Clichy, France
Contact: Pascal HAMMEL, Dr         
Principal Investigator: Pascal HAMMEL, MD         
Hôpital Henri Mondor Recruiting
Creteil, France
Contact: Christophe TOURNIGAND, PhD         
Principal Investigator: Christophe TOURNIGAND, PhD         
Centre Georges François Leclerc Recruiting
Dijon, France
Contact: François GHIRINGHELLI, MD         
Principal Investigator: François GHIRINGHELLI, MD         
CHD Vendée Recruiting
La Roche Sur Yon, France
Contact: Roger FAROUX, MD         
Principal Investigator: Roger FAROUX, MD         
Institut Hospitalier Franco-Britannique Recruiting
Levallois Perret, France
Contact: Benoist CHIBAUDEL, MD         
Principal Investigator: Benoist CHIBAUDEL, MD         
Centre Léon Bérard Not yet recruiting
Lyon, France
Contact: Françoise DESSEIGNE, MD         
Principal Investigator: Françoise DESSEIGNE, MD         
CH Saint Joseph Saint Luc Recruiting
Lyon, France
Contact: Denis PERE VERGE, MD         
Principal Investigator: Denis PERE VERGE, MD         
Hôpital Européen Not yet recruiting
Marseille, France
Contact: Yves RINALDI, MD         
Principal Investigator: Yves RINALDI, MD         
CH Mont de Marsan Recruiting
Mont de Marsan, France
Contact: Jérome DAUBA, MD         
Principal Investigator: Jérome DAUBA, MD         
Centre Hospitalier de Belfort Not yet recruiting
Montbéliard, France
Contact: Stefano KIM, MD         
Principal Investigator: Stefano KIM, MD         
Hôpital Cochin Recruiting
Paris, France
Contact: François GOLDWASSER, MD         
Principal Investigator: François GOLDWASSER, MD         
Hôpital Saint Antoine Recruiting
Paris, France
Contact: Marie-Line GARCIA LARNICOL, MD         
Principal Investigator: Marie-Line GARCIA LARNICOL, MD         
CHU Robert Debré Recruiting
Reims, France
Contact: Julien VOLET, MD         
Principal Investigator: Julien VOLET, MD         
Hôpital FOCH Recruiting
Suresnes, France
Contact: May MABRO, MD         
Principal Investigator: May MABRO, MD         
Institut de cancérologie de Lorraine Recruiting
Vandoeuvre Les Nancy, France
Contact: Thierry CONROY, MD         
Principal Investigator: Thierry CONROY, MD         
Sponsors and Collaborators
GERCOR - Multidisciplinary Oncology Cooperative Group
Principal Investigator: Pascal Hammel, PhD Hôpital Beaujon

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GERCOR - Multidisciplinary Oncology Cooperative Group
ClinicalTrials.gov Identifier: NCT02184663     History of Changes
Other Study ID Numbers: APACaP D13-1
2014-A00228-39 ( Other Identifier: Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) )
First Posted: July 9, 2014    Key Record Dates
Last Update Posted: February 2, 2018
Last Verified: January 2018

Keywords provided by GERCOR - Multidisciplinary Oncology Cooperative Group:
Pancreatic cancer
Adapted physical activity (APA)
Quality of life

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases